L26/P-839 AMH-guided HP-hMG supplementation to individualized follitropin delta in an NHS IVF/ICSI cohort is associated with higher blastocyst yield, low OHSS and modest incremental cost
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von C. Gilling-Smith und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Study question In UK NHS-funded first IVF/ICSI cycles, does AMH-guided HP-hMG supplementation to algorithm-dosed follitropin delta increase usable blastocyst yield and cost-efficiency without increasing OHSS? Summary answer AMH-guided HP-hMG supplementation to algorithm-dosed follitropin delta was associated with multiple usable blastocysts and no moderate/severe OHSS, supporting funded frozen transfers at modest medication cost. What is known already Follitropin delta is dosed by an AMH and weight-based algorithm with a capped first-cycle dose and a fixed daily dose in women with AMH <15 pmol/L. Randomised trials show reduced incidence of moderate and severe ovarian hyperstimulation syndrome (OHSS) and fewer extreme responses compared with conventional recombinant FSH (rFSH) dosing. However, the algorithm may deliver suboptimal oocyte/embryo yield in some lower-reserve patients. Blended protocols combining rFSH with HP-hMG (providing hCG-driven LH activity) have reported higher oocyte and good-quality blastocyst yield, but evidence remains limited and no consensus exists on AMH-guided dosing. Study design, size, duration This was a single-centre prospective cohort of NHS patients undergoing their first IVF/ICSI cycle using individualised follitropin delta per manufacturer algorithm plus AMH-stratified HP-hMG using a sliding-scale dose-dependent supplementation. The first 100 consecutive completed first fresh IVF or ICSI cycles during the initial 6 months of implementation were analysed. Participants/materials, setting, methods Women aged 18–42 years (BMI 19–30 kg/m²; AMH ≥5.4 pmol/L) underwent stimulation with individualised follitropin delta (according to manufacturer algorithm) plus HP-hMG from stimulation day 1 divided into 3 groups: 150 IU (AMH 5.4–14.9), 75 IU (15–24.9) or 37.5 IU (>25). Final oocyte maturation was triggered with hCG unless estradiol ≥15,000 pmol/L, when GnRH-agonist trigger was used. Outcomes were oocyte yield, MII oocytes, usable blastocysts (≥1BB), freeze-all rate, OHSS and direct cycle costs. Main results and the role of chance Of the 120 patients recruited, 100 completed a fresh IVF or ICSI cycle and three protocol deviations were excluded from the analysis (n = 97). Groups were defined by AMH and corresponding HP-hMG dose: Group 1 (AMH 5.4–14.9 pmol/L; HP-hMG 150 IU), Group 2 (15–24.9; 75 IU) and Group 3 (>25; 37.5 IU). Mean (±SD) oocytes retrieved increased from Group 1–3 (12.7±7.2; 15.9±7.1; 20.2±8.4), as did MII oocytes (10.8±6.5; 13.7±6.7; 16.6±7.9) and usable blastocysts (≥1BB) (2.3±1.8; 3.1±2.1; 4.0±2.8). Freeze-all rates were 14%, 24% and 50%, and cycles with zero usable blastocysts were 11.4%, 6.9% and 8.3% respectively. No moderate or severe OHSS cases occurred; mild OHSS was 0%, 10% and 4%. respectively. Incremental gonadotropin cost attributable to HP-hMG was 8.7%, 7.7% and 6.1% of total cycle cost in Groups 1–3. A frozen embryo replacement cycle was estimated to cost 74.4% less than an additional fresh IVF cycle and 77.6% less than an additional ICSI cycle (based on local NHS costing) Limitations, reasons for caution This was a non-randomised single-centre cohort with no contemporaneous control and limited follow-up. Cost estimates are centre-specific and cumulative live birth outcomes from frozen transfers are not yet available. Wider implications of the findings In England, commissioning commonly limits NHS funding to a single IVF cycle (currently the case for 62% of all commissioning bodies); a ‘full cycle’ includes fresh transfer plus all resulting frozen transfers. Increasing usable blastocysts may improve cumulative outcomes within one funded stimulation by enabling more lower-cost frozen transfers. Trial registration number No
Zitieren
APA
Gilling-Smith, C., Palmer, C., Gilling-Ulph, C., & Fatum, M. (2026). L26/P-839 AMH-guided HP-hMG supplementation to individualized follitropin delta in an NHS IVF/ICSI cohort is associated with higher blastocyst yield, low OHSS and modest incremental cost. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1166
Vancouver
Gilling-Smith C, Palmer C, Gilling-Ulph C, Fatum M. L26/P-839 AMH-guided HP-hMG supplementation to individualized follitropin delta in an NHS IVF/ICSI cohort is associated with higher blastocyst yield, low OHSS and modest incremental cost. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1166
BibTeX
@article{GillingSmith2026,
author = {Gilling-Smith, C. and Palmer, C. and Gilling-Ulph, C. and Fatum, M.},
title = {L26/P-839 AMH-guided HP-hMG supplementation to individualized follitropin delta in an NHS IVF/ICSI cohort is associated with higher blastocyst yield, low OHSS and modest incremental cost},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1166}
}
EUVIMED